Activity

159), HE-BMD (beta-estimate 0.009, 95% CI – 0.043 to 0.061, SE0.027, P value = 0.727), or fracture (beta-estimate 0.008, 95% CI – 0.071 to 0.087, SE0.041, P value = 0.844). These results were also confirmed by multiple sensitivity analyses. Contrary to the findings of observational studies, our results do not reveal a causal role of depression in osteoporosis or fracture.

Multiple revision hip arthroplasties and critical trauma might cause severe bone loss that requires proximal femoral replacement (PFR). The aim of this retrospective study was to analyse complication- and revision-free survivals of patients who received modular megaprostheses in an attempt to reconstruct massive non-neoplastic bone defects of the proximal femur. Questions/purposes (1) What were general complication rates and revision-free survivals following PFR? (2) What is the incidence of complication specific survivals? (3) What were risk factors leading to a diminished PFR survival?

Twenty-eight patients with sufficient follow-up after receiving a modular proximal femoral megaprosthesis were identified. The indications for PFR included prosthetic joint infection (PJI), periprosthetic fracture, aseptic loosening, non-union and critical femoral fracture. Complications were grouped according to the ISOLS-classification of segmental endoprosthetic failure by Henderson et al. RESULTS Overall, the complicahould be advocated in cases of impaired bone quality.Two novel Gram-stain-negative, non-motile, aerobic, rod-shaped, circular, convex, red-colored and UV-tolerant strains BT594T and BT646T were isolated from soil collected in Guri city (37° 36′ 0″ N, 127° 9′ 0″ E) and Gwangju city (37° 22′ 0″ N, 127° 17′ 0″ E), respectively, South Korea. 16S rDNA sequence analysis indicated that strains BT594T and BT646T belong to a distinct lineage within the genus Hymenobacter (family Hymenobacteraceae, order Cytophagales, class Cytophagia, phylum Bacteroidetes, kingdom Bacteria). read more The 16S rDNA gene sequence similarity between the two strains BT594T and BT646T was 96.2%. The strain BT594T was closely related to Hymenobacter psychrotolerans Tibet-IIU11T (97.0% 16S rDNA gene similarity) and Hymenobacter tibetensis XTM003T (96.3%). The strain BT646T was closely related to Hymenobacter psychrotolerans Tibet-IIU11T (98.6%), Hymenobacter kanuolensis T-3 T (96.8%) and Hymenobacter perfusus LMG 26000 T (96.7%). The two strains were found to have the same quinone system, with MK-7 as the major respiratory quinone. The major polar lipids of strains BT594T and BT646T were phosphatidylethanolamine (PE) and aminophospholipids (APL). The major cellular fatty acids of strain BT594T were anteiso-C150 (17.9%), iso-C150 (16.1%) and summed feature 3 (C161 ω6c / C161 ω7c) (10.0%). The major cellular fatty acids of strain BT646T were summed feature 3 (C161 ω6c / C161 ω7c) (18.3%), C160 (17.2%) and summed feature 4 (iso-C171 I / anteiso-C171 B) (14.5%). Based on the polyphasic analysis, strains BT594T and BT646T can be suggested as two novel bacterial species within the genus Hymenobacter and the proposed names are Hymenobacter guriensis and Hymenobacter duratus, respectively. The type strain of Hymenobacter guriensis is BT594T (= KCTC 21863 T = NBRC 114853 T) and the type strain of Hymenobacter duratus is BT646T (= KCTC 21915 T = NBRC 114854 T).Periampullary neoplasms are a heterogeneous group of different tumor entities arising from the periampullary region, of which pancreatic ductal adenocarcinoma (PDAC) is the most common subgroup with 60-70%. As typical for pancreatic adenocarcinomas, periampullary pancreatic cancer is characterized by an aggressive growth and early systemic progression. Due to the anatomical location in close relationship to the papilla of Vater symptoms occur at an earlier stage of the disease, so that treatment options and prognosis are overall more favorable compared to pancreatic carcinomas at other locations. Nevertheless, the principles of treatment for periampullary pancreatic cancer are not substantially different from the standards for pancreatic cancer at other locations. A potentially curative approach for non-metastatic periampullary pancreatic cancer is a multimodal therapy concept, which includes partial pancreatoduodenectomy as a radical oncological resection in combination with a systemic adjuvant chemotherapy. As a result, long-term survival can be achieved in patients with favorable prognostic factors. In addition, with the continous development of surgery and systemic treatment potentially curative treatment concepts for advanced initially nonresectable tumors were also established, after completion of neoadjuvant treatment. This article presents the current surgical principles of a radical oncological resection for periampullary pancreatic cancer in the context of a multimodal treatment concept with an outlook for future developments of treatment.In the past 25 years, treatment of metastatic colorectal cancer (mCRC) has undergone profound changes. The approval of newer chemotherapeutics such as irinotecan and oxaliplatin was followed in 2005 by the first targeted therapies, for example, monoclonal antibodies directed against the epidermal growth factor receptor (EGFR), as cetuximab and panitumumab, or the angiogenesis inhibitors bevacizumab, ramucirumab, and aflibercept. With the rapidly progressing molecular characterization of mCRC in the last 10 years and the classification of the disease in four consensus subtypes, further changes are emerging, which will promote, among other things, the introduction of protein-kinase inhibitors developed for specific molecular aberrations as well as immune checkpoint inhibitors into the treatment algorithm.Thorough molecular pathologic testing is indispensable today for guideline-compliant treatment of mCRC patients. In addition to RAS testing as a precondition for the therapy decision with regard to cetuximab and panitumumab, BRAF testing is of considerable relevance to allow decision making with regard to the newly approved chemotherapy-free combination of the BRAF inhibitor encorafenib and cetuximab in cases where a BRAF-V600E mutation is detected. Additional diagnostic tests should also include genome instability (microsatellite instability). Overall, more and more molecular alterations need to be investigated simultaneously, so that the use of focused next-generation sequencing is increasingly recommended.This overview describes the prognostic relevance of BRAF testing in the context of molecular pathologic diagnostics of mCRC, presents new treatment options for BRAF-mutated mCRC patients, and explains which modern DNA analytical and immunohistochemical methods are available to detect BRAF mutations in mCRC patients.